等待开盘 11-07 09:30:00 美东时间
-0.110
-0.15%
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据CorVel业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 2025年9月季度营收达到2.4亿美元,较2024年9月季度的2.24亿美元增长7%,实现1600万美元的增长。 **盈利能力:** 调整后每股收益为0.54美元,较去年同期的0.45美元增长20%(已调整2024年12月三股拆一股的影响);净利润从去年同期的2300万美元增长至2800万美元。 **现金状况:** 季度末现金余额为2.07亿美元,公司保持无债务状态;应收账款周转天数(DSO)为40天,较去年同期改善2天。 **股票回购:** 本季度回购1
11-05 12:10
CorVel shares are trading higher after the company reported a year-over-year in...
11-05 00:11
CorVel (NASDAQ:CRVL) reported quarterly earnings of $0.54 per share. This is a 20 percent increase over earnings of $0.45 per share from the same period last year. The company reported $239.643 million in sales this
11-04 19:13
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
CorVel Corporation reported Q3 2025 results with revenues of $240 million, up 7% from the prior year, and earnings per share of $0.54, a 20% increase. The company also saw cash reserves of $207 million and repurchased $12.8 million of stock. Growth initiatives include workforce development through CorVel University and AI enhancements across operations, despite market challenges.
11-04 11:15
CorVel Corporation will host a live webcast on November 4 at 11:30 AM ET to discuss its quarterly earnings and introduce new CFO Brian Nichols. The event, led by CEO Michael Combs, will cover financial performance, strategic initiatives, and include a Q&A session. The webcast will be available via the provided link, with a replay option. Investors may submit questions in advance. CorVel specializes in risk management solutions, using technology t...
10-21 13:13
Corvus Pharmaceuticals announced interim results from a Phase 1b/2 trial assessing ciforadenant in combination with ipilimumab and nivolumab as a potential first-line therapy for metastatic renal cell cancer (RCC). The trial enrolled 50 patients with advanced RCC, demonstrating the triplet therapy's feasibility, tolerability, and encouraging activity. Key highlights include a 34% deep response rate and a 46% overall response rate, with the median...
10-17 14:00
The most oversold stocks in the health care sector presents an opportunity to b...
10-06 18:23
Corvus Pharmaceuticals announced the appointment of David Moore to its Board of Directors. Moore, Executive Vice President at Novo Nordisk, brings 27 years of industry experience in strategy, commercial operations, and business development. His expertise, particularly in successful drug franchises like Ozempic and Wegovy, is expected to strengthen Corvus's ITK inhibitor platform for cancer and immune diseases. Moore expressed excitement about con...
10-02 20:01
稳定币市场快速发展,总流通量达2870亿美元,USDT和USDC占据主导地位。然而,发行方在依赖公链的同时获利有限,促使越来越多的发行方开始自建公链。例如,Tether推出Plasma和Stable链,Circle推出Arc链,这些新链旨在优化交易体验、降低用户门槛并提高合规性。通过自建公链,发行方不仅能够增强价值捕获,还能拓展多元化商业模式。未来,稳定币公链将与传统公链形成分工互补,推动加密市场进入“稳定币—公链双轮驱动”的新阶段。
09-22 13:23